Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Neogenomics

11/29/2021 | 05:30pm EST


ę MT Newswires 2021
All news about NEOGENOMICS, INC.
01/19NEOGENOMICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/19Neogenomics, Inc. Announces Resignation of Kevin Johnson from Board of Directors
CI
01/12SVB Leerink Adjusts NeoGenomics Price Target to to $45 From $50, Maintains Outperform R..
MT
01/11NeoGenomics Unit Receives CE Mark for Its RaDaR Liquid Biopsy Assay
MT
01/11NEOGENOMICS : Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimburse..
PU
2021Cowen Starts NeoGenomics at Outperform with $42 Price Target
MT
2021NeoGenomics Appoints David Eberhard Chief Medical Officer for Inivata
MT
2021NEOGENOMICS : Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid B..
PU
2021NEOGENOMICS : to Leverage Thermo Fisher Scientific's Ion Torrent Genexus System in Upcomin..
PU
2021Needham Adjusts NeoGenomics' Price Target to $41 From $48; Buy Rating Kept
MT
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Financials (USD)
Sales 2021 485 M - -
Net income 2021 0,68 M - -
Net Debt 2021 288 M - -
P/E ratio 2021 -12 928x
Yield 2021 -
Capitalization 2 658 M 2 658 M -
EV / Sales 2021 6,08x
EV / Sales 2022 5,32x
Nbr of Employees 1 700
Free-Float 95,7%
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 21,59 $
Average target price 47,64 $
Spread / Average Target 121%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
William Bishop Bonello Chief Financial Officer
Lynn A. Tetrault Non-Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors